N-(6-tert-butyl-3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyridine-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-(6-tert-butyl-3-carbamoyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)pyridine-3-carboxamide
• 化学式: C₁₉H₂₃N₃O₂S
• 分子量: 357.5
• InChiKey: PUWJIALIJZWLIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR DE LA DOPAMINE 1 ET PROCÉDÉ D'UTILISATION ASSOCIÉ
  申请人：US HEALTH

  公开号：WO2019173437A1

  公开（公告）日：2019-09-12

  Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein R1 R6 and R11 R13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.

  本发明揭示了式(I)和式(III)的化合物，用于治疗或预防哺乳动物中D1多巴胺受体激动剂的激活所响应的疾病或障碍，其中R1、R6和R11、R13如本文所定义。此类疾病或障碍的例子包括阿尔茨海默病、精神分裂症、帕金森病、运动障碍和亨廷顿病。
• POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF
  申请人：Sibley David R.

  公开号：US20210040074A1

  公开（公告）日：2021-02-11

  Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein m, n, R 1 -R 6 , and R 11 -R 13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.